Interleukin-6: A therapeutic Jekyll and Hyde in gastrointestinal and hepatic diseases

Gut

Volumn 59, Issue 2, 2010, Pages 149-151

  Danese, Silvio ^a   Gao, Bin ^b  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMYLOID A PROTEIN; C REACTIVE PROTEIN; ENDOTOXIN; FIBRINOGEN; GLYCOPROTEIN GP 130; INTERFERON REGULATORY FACTOR 4; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; JANUS KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; RECEPTOR ANTIBODY; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; CANCER INHIBITION; CANCER STAGING; CELL DAMAGE; CELL DEATH; CELL DIFFERENTIATION; CELL SURVIVAL; COLON CANCER; ENTERITIS; EPITHELIUM CELL; GASTROINTESTINAL DISEASE; GENE EXPRESSION; HUMAN; HYPERPLASIA; INTESTINE INJURY; LAMINA PROPRIA; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER PROTECTION; LIVER REGENERATION; MONONUCLEAR CELL; NOTE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REPERFUSION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TH17 CELL; UPREGULATION; VASCULAR ENDOTHELIUM;

COLONIC NEOPLASMS; DIGESTIVE SYSTEM DISEASES; HUMANS; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-6; LIVER DISEASES;

EID: 77149147422     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2008.173534     Document Type: Note

References (16)

1. Naka T, Nishimoto N, Kishimoto T. The paradigm of IL-6: from basic science to medicine. Arthritis Res 2002;4:S233-42.
2. Gabay C. Interleukin-6 and chronic inflammation. Arthritis Res Ther 2006;8:S3.
3. Atreya R, Neurath MF. Signaling molecules: the pathogenic role of the IL-6/STAT-3 trans signaling pathway in intestinal inflammation and in colonic cancer. Curr Drug Targets 2008;9:369-74.
4. Weigmann B, Lehr HA, Yancopoulos G, et al. The transcription factor NFATc2 controls IL-6-dependent T cell activation in experimental colitis. J Exp Med 2008;205:2099-110.
5. Mudter J, Amoussina L, Schenk M, et al. The transcription factor IFN regulatory factor-4 controls experimental colitis in mice via T cell-derived IL-6. J Clin Invest 2008;118:2415-26.
6. Atreya R, Mudter J, Finotto S, et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nat Med 2000;6:583-8.
7. Ito H, Takazoe M, Fukuda Y, et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 2004;126:989-96.
8. Jin X, Zimmers T, Zhang Z, et al. IL-6 is an important in vivo inhibitor of intestinal epithelial cell death in mice. Gut 2010;59:186-96.
9. Becker C, Fantini MC, Schramm C, et al. TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 2004;21:491-501.
10. Gao B. Cytokines, STATs and liver disease. Cell Mol Immunol 2005;2:92-100.
11. Klein C, Wustefeld T, Assmus U, et al. The IL-6-gp130-STAT3 pathway in hepatocytes triggers liver protection in T cell-mediated liver injury. J Clin Invest 2005;115:860-9.
12. Haga S, Terui K, Zhang HQ, et al. Stat3 protects against Fas-induced liver injury by redox-dependent and -independent mechanisms. J Clin Invest 2003;112:989-98.
13. Horiguchi N, Wang L, Mukhopadhyay P, et al. Cell type-dependent pro- and anti-inflammatory role of signal transducer and activator of transcription 3 in alcoholic liver injury. Gastroenterology 2008;134:1148-58.
14. Hong F, Radaeva S, Pan HN, et al. Interleukin 6 alleviates hepatic steatosis and ischemia/reperfusion injury in mice with fatty liver disease. Hepatology 2004;40:933-41.
15. Sun Z, Klein AS, Radaeva S, et al. In vitro interleukin-6 treatment prevents mortality associated with fatty liver transplants in rats. Gastroenterology 2003;125:202-15.
16. Naugler WE, Sakurai T, Kim S, et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007;317:121-4.